Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel. Internal Medicine Journal. 46 (10): 1189–1197. October 2016. doi:10.1111/imj.13215. PMID27527376.
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 286 (18): 2270–9. November 2001. doi:10.1001/jama.286.18.2270. PMID11710893.
Pharmacogenetics in the laboratory and the clinic. The New England Journal of Medicine. 348 (6): 553–6. February 2003. doi:10.1056/NEJMe020173. PMID12571264.
Pharmacogenomics--drug disposition, drug targets, and side effects. The New England Journal of Medicine. 348 (6): 538–49. February 2003. doi:10.1056/NEJMra020526. PMID12571262.
Adverse drug reactions: a potential role for pharmacists. The British Journal of General Practice. 65 (639): 511.1—511. October 2015. doi:10.3399/bjgp15X686821. PMID26412813.
Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel. Internal Medicine Journal. 46 (10): 1189–1197. October 2016. doi:10.1111/imj.13215. PMID27527376.
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 286 (18): 2270–9. November 2001. doi:10.1001/jama.286.18.2270. PMID11710893.
Pharmacogenetics in the laboratory and the clinic. The New England Journal of Medicine. 348 (6): 553–6. February 2003. doi:10.1056/NEJMe020173. PMID12571264.
Pharmacogenomics--drug disposition, drug targets, and side effects. The New England Journal of Medicine. 348 (6): 538–49. February 2003. doi:10.1056/NEJMra020526. PMID12571262.
Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacology Bulletin. 36 (3): 5–21. 2002. PMID12473961.
Adverse drug reactions: a potential role for pharmacists. The British Journal of General Practice. 65 (639): 511.1—511. October 2015. doi:10.3399/bjgp15X686821. PMID26412813.